MX2022002116A - Peptidos para tratar la atrofia muscular. - Google Patents

Peptidos para tratar la atrofia muscular.

Info

Publication number
MX2022002116A
MX2022002116A MX2022002116A MX2022002116A MX2022002116A MX 2022002116 A MX2022002116 A MX 2022002116A MX 2022002116 A MX2022002116 A MX 2022002116A MX 2022002116 A MX2022002116 A MX 2022002116A MX 2022002116 A MX2022002116 A MX 2022002116A
Authority
MX
Mexico
Prior art keywords
peptides
muscle
subjects
muscle atrophy
atrophy
Prior art date
Application number
MX2022002116A
Other languages
English (en)
Inventor
Nora Khaldi
Cyril Lopez
Alessandro Adelfio
Original Assignee
Nuritas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuritas Ltd filed Critical Nuritas Ltd
Publication of MX2022002116A publication Critical patent/MX2022002116A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/40—Shaping or working of foodstuffs characterised by the products free-flowing powder or instant powder, i.e. powder which is reconstituted rapidly when liquid is added
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Botany (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

El solicitante ha descubierto una serie de péptidos que son capaces de fosforilar la proteína ribosómica S6 (rpS6) en un rango de concentraciones en ensayos celulares in vitro de forma dependiente de la dosis. RPS6 es un sustrato clave para las proteínas quinasas y es fosforilada por factores de crecimiento y mitógenos durante el crecimiento y la división celular. Este es un paso clave en la síntesis de nuevas proteínas en el tejido muscular esquelético. Los péptidos descritos tienen también la capacidad de reducir la expresión de los transcritos de ARNm (TRIM63 y FBXO32) que están directamente relacionados con el aumento de la degradación de las proteínas, lo que resulta en la atrofia progresiva del músculo esquelético. Además, el aumento de la atrofia muscular está relacionado con el aumento sistémico del TNFa circulante. Los péptidos descritos en el presente documento también conducen a la reducción de la expresión de TNFa en las células inmunes circulantes. Los péptidos se pueden utilizar para promover el crecimiento muscular y la salud muscular en sujetos que presentan atrofia muscular, por ejemplo, sujetos de edad avanzada, personas físicamente inactivas y sujetos que tienen indicaciones caracterizadas por la atrofia muscular (es decir, esclerosis múltiple y poliomielitis).
MX2022002116A 2019-08-20 2020-08-14 Peptidos para tratar la atrofia muscular. MX2022002116A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19192689 2019-08-20
PCT/EP2020/072937 WO2021032650A1 (en) 2019-08-20 2020-08-14 Peptides for treating muscle atrophy

Publications (1)

Publication Number Publication Date
MX2022002116A true MX2022002116A (es) 2022-03-17

Family

ID=67659544

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002116A MX2022002116A (es) 2019-08-20 2020-08-14 Peptidos para tratar la atrofia muscular.

Country Status (10)

Country Link
US (1) US20220287347A1 (es)
EP (2) EP4017518A1 (es)
JP (1) JP2022545265A (es)
KR (1) KR20220103695A (es)
CN (1) CN114650834A (es)
AU (1) AU2020334196A1 (es)
BR (1) BR112022002727A2 (es)
CA (1) CA3147981A1 (es)
MX (1) MX2022002116A (es)
WO (1) WO2021032650A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023096232A1 (ko) * 2021-11-25 2023-06-01 (주)네오크레마 신규 펩티드 및 이의 용도
WO2023096233A1 (ko) * 2021-11-25 2023-06-01 (주)네오크레마 신규 펩티드 및 이의 용도
KR20230170490A (ko) * 2022-06-10 2023-12-19 (주)케어젠 근육 손실 저해 및 근육량 증진 활성을 갖는 펩타이드 및 이의 용도

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
US5972650A (en) 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
EP1033405A3 (en) * 1999-02-25 2001-08-01 Ceres Incorporated Sequence-determined DNA fragments and corresponding polypeptides encoded thereby
US20110214206A1 (en) * 1999-05-06 2011-09-01 La Rosa Thomas J Nucleic acid molecules and other molecules associated with plants
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
EP1392859B1 (en) 2001-01-16 2006-05-10 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
AU2004270102B2 (en) 2003-05-23 2009-10-01 Pestka Biomedical Laboratories, Inc. Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections
US20070053845A1 (en) 2004-03-02 2007-03-08 Shiladitya Sengupta Nanocell drug delivery system
WO2006076588A1 (en) * 2005-01-13 2006-07-20 Regenerx Biopharmaceuticals, Inc. Method of treating or preventing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or restore tissue adversely affected by said disease
US8105572B2 (en) 2007-05-18 2012-01-31 New York University Method of treating tuberculosis with interferons
US7771997B2 (en) 2007-06-04 2010-08-10 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
EP2050437A1 (en) 2007-10-15 2009-04-22 Laboratoires SMB Improved pharmaceutical dry powder compositions for inhalation.
ES2397890B1 (es) 2011-03-25 2014-02-07 Lipotec, S.A. Péptidos útiles en el tratamiento y/o cuidado de la piel y/o mucosas y su uso en composiciones cosméticas o farmacéuticas.
EP2771349B1 (en) * 2011-09-16 2020-02-26 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
KR20170002846A (ko) * 2015-06-30 2017-01-09 (주)아모레퍼시픽 콩잎 추출물을 유효성분으로 함유하는 근질환 억제 및 예방용 조성물
EP3117831A1 (en) * 2015-07-16 2017-01-18 Nuritas Limited Peptides for use in promoting transport of glucose into skeletal muscle
EP3118215A1 (en) * 2015-07-16 2017-01-18 Nuritas Limited Anti-inflammatory peptides, and uses thereof
EP3118216A1 (en) * 2015-07-16 2017-01-18 Nuritas Limited Cellular growth and proliferation promoting peptides, and uses thereof
KR102623786B1 (ko) * 2017-12-06 2024-01-11 어비디티 바이오사이언시스 인크. 근위축증 및 근긴장성 이영양증을 치료하는 조성물 및 방법

Also Published As

Publication number Publication date
EP4218787A3 (en) 2023-12-20
AU2020334196A1 (en) 2022-03-03
BR112022002727A2 (pt) 2022-08-23
JP2022545265A (ja) 2022-10-26
EP4218787A2 (en) 2023-08-02
KR20220103695A (ko) 2022-07-22
CA3147981A1 (en) 2021-02-25
US20220287347A1 (en) 2022-09-15
WO2021032650A1 (en) 2021-02-25
EP4017518A1 (en) 2022-06-29
CN114650834A (zh) 2022-06-21

Similar Documents

Publication Publication Date Title
MX2022002116A (es) Peptidos para tratar la atrofia muscular.
Zhang et al. Irisin exerts dual effects on browning and adipogenesis of human white adipocytes
Marcotorchino et al. Vitamin D reduces the inflammatory response and restores glucose uptake in adipocytes
KR102245702B1 (ko) 셀렌을 포함하는 조성물 및 미토콘드리아 기능장해와 관련된 질병 또는 상태의 치료와 예방을 위한 이의 용도
Jeong et al. Vitamin C-treated murine bone marrow-derived dendritic cells preferentially drive naïve T cells into Th1 cells by increased IL-12 secretions
Boonloh et al. Rice bran protein hydrolysates prevented interleukin-6-and high glucose-induced insulin resistance in HepG2 cells
Peters et al. Dose-dependent effects of leucine supplementation on preservation of muscle mass in cancer cachectic mice
Choi et al. Fisetin inhibits osteoclast differentiation via downregulation of p38 and c‐Fos‐NFATc1 signaling pathways
Zhang et al. Protein nutritional support: the classical and potential new mechanisms in the prevention and therapy of sarcopenia
MX339068B (es) Metodos y composiciones para el tratamiento de defectos oseos con poblaciones de celulas placentarias.
CA3168146A1 (en) Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (rms)
Lin et al. Interleukin‐17 regulates the expressions of RANKL and OPG in human periodontal ligament cells via TRAF 6/TBK 1‐JNK/NF‐κB pathways
AU2001277539A1 (en) Pre-adipose cell lines
EA202191508A1 (ru) Размножение естественных клеток-киллеров и клеток ilc3 с использованием новых ароматических соединений
Ceci et al. Skeletal muscle differentiation: role of dehydroepiandrosterone sulfate
Miyata et al. Mitogen‐activated protein kinase/extracellular signal‐regulated protein kinase activation of cultured human dental pulp cells by low‐power gallium‐aluminium‐arsenic laser irradiation
MX2020004397A (es) Uso de suplementos de aminoacidos para mejorar la sintesis de proteinas musculares.
AU2020344620A8 (en) Implant comprising first and second sets of pillars for attaching a tendon or ligament to a hard tissue
Wang et al. Tumor suppressor gene ING3 induces cardiomyocyte hypertrophy via inhibition of AMPK and activation of p38 MAPK signaling
Sun et al. Resveratrol inhibits human visceral preadipocyte proliferation and differentiation in vitro
WO2019066617A3 (ko) 항 c-met 항체 및 이의 용도
Morita et al. Novel Mechanisms Modulating Palmitate‐Induced Inflammatory Factors in Hypertrophied 3T3‐L1 Adipocytes by AMPK
Al-Shaeli et al. Anti-neoplastic effect of epigallocatechin gallate on breast cancer cells through glucose metabolism
Rahman et al. Nox2 activity is required in obesity‐mediated alteration of bone remodeling
Pellegrino et al. Amino acid supplementation counteracts metabolic and functional damage in the diabetic rat heart